Document is current
Any future updates will be listed below
-
Authors
Chen, Lingyan https://orcid.org/0000-0003-3750-6761
Peters, James E. https://orcid.org/0000-0002-9415-3440
Prins, Bram https://orcid.org/0000-0001-5774-034X
Persyn, Elodie https://orcid.org/0000-0001-9104-1972
Traylor, Matthew
Surendran, Praveen
Karthikeyan, Savita
Yonova-Doing, Ekaterina
Di Angelantonio, Emanuele
Roberts, David J.
Watkins, Nicholas A.
Ouwehand, Willem H. https://orcid.org/0000-0002-7744-1790
Danesh, John
Lewis, Cathryn M. https://orcid.org/0000-0002-8249-8476
Bronson, Paola G. https://orcid.org/0000-0001-9996-9812
Markus, Hugh S.
Burgess, Stephen https://orcid.org/0000-0001-5365-8760
Butterworth, Adam S. https://orcid.org/0000-0002-6915-9015
Howson, Joanna M. M. https://orcid.org/0000-0001-7618-0050
-
Funding
Funding for this research was provided by:
British Heart Foundation (RG/16/4/32218)
NIHR Cambridge Biomedical Research Centre
- License Information
-
More Information
Article History
Received: 16 October 2021
Accepted: 28 September 2022
First Online: 17 October 2022
Competing interests
: J.M.M.H., L.C., M.T. and E.Y.-D. became full-time employees of Novo Nordisk Ltd. during the drafting of this manuscript. J.D. serves on scientific advisory boards for AstraZeneca, Novartis and UK Biobank, and has received multiple grants from academic, charitable and industry sources for the submitted work. A.S.B. reports institutional grants from AstraZeneca, Bayer, Biogen, BioMarin, Bioverativ, Novartis, Regeneron and Sanofi and personal fees from Novartis. P.G.B. is a full-time employee of Biogen Inc. The remaining authors declare no competing interests.
